Pureos Bioventures β 2024 Investments
3 investments dated 2024 Β· listed companies and verified rows first Β· show all
Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases.
BiotechMedical DevicesZurich, CH
Co-investorsKurma PartnersYsios CapitalAdjuvant CapitalFresenius Medical Care VenturesVerve Venturesredalpine
.jpeg){kind=logo}
Vico Therapeutics develops targeted genetic medicines for neurological disorders, with a focus on antisense oligonucleotide therapies designed to address the underlying genetic causes of diseases like Huntington's disease and spinocerebellar ataxias.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Luc Dochez(Chair and Founder)inJosh Mandel-Brehm(Co-Founder)in
Co-investorsDroia VenturesKurma PartnersEQT Life SciencesSeroba Life SciencesEurazeoIdinvest Partners
VICO provides AI-generated forecasts and event risk ratings that track and triangulate analyst views into continuous time series data.
AI & Machine LearningData & InfrastructureFintech
Co-investorsAIN VenturesMultiball CapitalDroia VenturesEQT Life SciencesEurazeoKurma Partners
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.